Overview of Alburex

Property	Description
Active ingredient	Human Albumin
Form	Solution for intravenous infusion
Pharmacological class	Plasma volume expander
General purpose	Restoration of fluid balance and plasma volume
Origin	Biological, derived from human plasma

Alburex is the trade name for a highly purified Human Albumin solution, which is classified as a plasma volume expander used in hospital settings. The medicine functions as a replacement for the essential plasma protein naturally found in human blood, which is crucial for managing fluid distribution. Its designation as a biological medicine reflects its direct natural origin from human plasma.

What Type of Medicine is Alburex and What is its Composition?

Alburex is classified pharmacologically as an agent affecting the blood and blood-forming organs, specifically belonging to the plasma fraction group. The active ingredient is Human Albumin (INN), a complex protein derived from donated human plasma that undergoes rigorous purification. This compound is essential for maintaining blood volume and fluid balance throughout the body. The medicine is presented as a sterile solution for intravenous infusion, making it a parenteral preparation that bypasses the digestive system when administered. This preparation is a single active ingredient product that is available in various concentrations, such as 5% and 20% solutions, allowing for tailored use depending on the required therapeutic effect.

What is the General Purpose of Alburex?

The general purpose of Alburex is to stabilize and restore the necessary plasma volume in the bloodstream, particularly in situations of significant loss. Human Albumin achieves this by generating oncotic pressure (also known as colloid osmotic pressure), which is the physical force required to draw fluid from the body's tissues back into the blood vessels. This action supports critical circulatory function by helping to regulate the body’s overall fluid balance and is generally utilized following conditions such as severe hypovolemia (low blood volume) or hypoproteinemia (low protein levels). Albumin administration is a key method for regulating the volume of plasma when protein deficiency or blood loss compromises circulation. Clinically, Alburex is often recognized as the appropriate choice when rapid, sustained replacement of oncotic activity is needed to maintain effective blood circulation and the proper distribution of water throughout the body.

Regulatory References

Physiology, Albumin - StatPearls - NCBI Bookshelf (NIH)

What side effects are possible with Alburex?

Possible Side Effects and Safety Information

The official safety information for Human Albumin (Alburex) is structured to describe adverse reactions by both the physiological system they affect and their expected frequency, based strictly on government regulatory documents.

Most reported adverse reactions are classified as uncommon, meaning they are expected to affect between 1 and 10 users in every 1,000. These often involve mild, infusion-related symptoms, which the regulatory label notes may include general symptoms like nausea, vomiting, pyrexia (fever), chills, and flushing (reddening of the skin).

Official Regulatory Classifications

Adverse Reaction Category	Examples of Listed Effects	System-Organ Class	Frequency in Regulatory Labeling
Hypersensitivity	Urticaria, Allergic reactions	Immune system disorders	Uncommon to Very Rare
Cardiovascular	Hypotension, Tachycardia	Vascular disorders, Cardiac disorders	Uncommon

Serious Adverse Reactions and Constraints

The regulatory label documents that the most severe, though very rare (affecting fewer than 1 in 10,000 users), reaction is anaphylactic shock and other severe allergic episodes. These serious events necessitate the immediate stopping of the infusion, as specified in regulatory prescribing information.

Safety constraints are explicitly documented for individuals where increasing blood volume presents a specific risk. Caution is required for patients with pre-existing conditions that are sensitive to fluid overload, such as cardiac insufficiency or severe anemia, to mitigate the risks of hypervolaemia (volume overload) or excessive haemodilution (blood thinning). These safety statements define the conditions under which the medicine's volume-expanding function must be monitored with particular care.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Alburex (Human Albumin) is defined in regulatory documents as a state of hypervolaemia (abnormal increase in blood volume) resulting from an excessively high infusion rate or total dose. Because the medicine functions as a plasma volume expander, overdose leads directly to cardiovascular overload.

Documented Overdose Manifestations and Actions

The onset of overdose is characterized by specific clinical signs. Patients must tell their doctor or healthcare professional immediately if they experience the following manifestations, as they require urgent attention:

Headache
Dyspnoea (breathing difficulty)
Jugular vein congestion
Increased blood pressure

At the first sign of cardiovascular overload, the infusion must be stopped immediately as mandated by regulatory authorities. The most severe or life-threatening outcome documented is pulmonary oedema (fluid accumulation in the lungs), which can result from uncorrected overload.

Overdose Management and Monitoring

No specific antidote is described in the official prescribing information. Management procedures focus on immediate cessation of the infusion and the initiation of symptomatic and supportive treatment to manage the volume overload. Continuous monitoring of haemodynamic parameters such as arterial blood pressure, pulse rate, and central venous pressure is required in these situations.

Special consideration is noted for populations with existing conditions, such as decompensated cardiac insufficiency, where hypervolaemia poses a special risk.

Therapeutic Uses of Alburex

What Alburex Treats: Main Uses and Benefits

Alburex is commonly used in clinical settings to provide support in conditions where the body's fluid balance and protein levels may be significantly affected. Its application is relevant for managing symptoms related to significant imbalances in blood volume and fluid distribution. The solution is generally used for managing circulating blood volume and is applied in clinical settings that involve acute or unstable symptom patterns.

The medication is relevant across therapeutic domains involving distressing symptoms of acute volume deficiency (hypovolemia), severe edema associated with fluid imbalances, and significant hypoalbuminemia (low protein levels). It is applied in situations such as assisting with symptoms in patients following traumatic injury or acute blood loss, providing supportive care in cases of severe burn injury, and managing fluid imbalances associated with conditions like ascites (fluid accumulation).

“Alburex helps manage symptoms that create noticeable physiological strain and supports the patient during difficult episodes of circulatory instability.”

Quick Fact: Relief for Circulatory Instability

Alburex is applied in contexts where additional support for symptom management is appropriate to help manage the volume required for blood circulation. This generally supports the patient during difficult episodes by easing distress related to circulatory instability and assists with maintaining comfort.

Managing Severe Fluid Accumulation

The medicine helps address symptom clusters that may become intense or disruptive, particularly the significant, abnormal swelling or edema that can occur when blood protein levels are low. It offers symptomatic relief that helps patients cope more steadily with difficult episodes of fluid imbalance and contributes to easing the overall symptom load.

Eligibility and Restrictions for Use

Who Can and Cannot Use Alburex?

Eligibility for Alburex (Human Albumin) is defined by official regulatory documentation, focusing on patient safety concerning its function as a plasma volume expander.

Absolute Contraindications (Must Not Use):

Condition
Hypersensitivity to human albumin or any excipient.
Severe Anemia.
Severe Cardiac Failure (heart failure) with normal or increased intravascular volume.

Populations Requiring Special Caution:

Use of Alburex requires special caution in conditions where the risk of volume overload (hypervolaemia) is high, including Hypertension, Pulmonary Edema, Esophageal Varices, and certain states of Renal Anuria.

Age-Related Eligibility:

Age Group	Regulatory Status
Adults & Older Adults	Established use.
Pediatric Patients	Use is accepted based on extensive clinical experience, though safety and effectiveness are not established in controlled clinical trials.

Pregnancy and Lactation Status:

Use during pregnancy and breastfeeding is conditional; it has not been established in controlled clinical trials and should only be administered if the clinical benefits outweigh the potential risks, as stated in official labeling.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Alburex (Human Albumin)

Interaction scope

Property	Official Regulatory Statement
Medicinal product categories with documented interactions	Angiotensin-Converting Enzyme (ACE) Inhibitors (in a specific procedural context). Protein hydrolysates or amino acid solutions. Solutions containing alcohol.
Specific interacting medicines (if explicitly listed)	The general class of ACE Inhibitors is specified.
Mechanistic basis of interactions (only if stated in label)	None documented for metabolic (CYP) or transporter-mediated pathways. Interactions are based on Physicochemical Incompatibility and Pharmacodynamic effects.
Timing-based interaction rules (if applicable)	The product must not be mixed with other medicinal products and must be administered separately.
Population-specific interaction notes (if applicable)	None documented in the context of drug-drug interactions.
Interaction-related restrictions	Strictly prohibited dilution with Water for Injection due to the risk of hemolysis. Must not be mixed with solutions containing alcohol or protein hydrolysates to avoid precipitation or destabilization.
Interactions with Food, Alcohol, Herbal Products	Alcohol is a strictly prohibited mixing agent. No documented interactions with food or herbal products.

Interaction classifications (high-level)

Property	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Contraindicated Combination (with Water for Injection). Warning/Precaution (with ACE Inhibitors during plasma exchange). Physicochemical Incompatibility (with protein hydrolysates/alcohol).
Regulatory basis (EMA / FDA / etc.)	Information derived from FDA DailyMed, Health Canada Product Monograph, and Australian Product Information.
Interaction-context constraints (as defined in official documents)	The pharmacodynamic interaction with ACE inhibitors is constrained to the context of a plasma exchange procedure.

Resulting interaction structure

Official interaction statements:

Co-administration is formally prohibited with Water for Injection due to the risk of hemolysis in the recipient.
The solution must not be mixed with protein hydrolysates or solutions containing alcohol because precipitation or destabilization may occur.
A specific pharmacodynamic warning exists regarding the co-administration of Albumin (Human) with ACE inhibitors; this carries a documented risk of potentially severe hypotension, particularly during a plasma exchange procedure.
The product must not be mixed with other medicinal products; if dilution is required, it must be performed only with specific isotonic solutions, such as 0.9% Sodium Chloride or 5% Glucose.

Connection to the overall interaction profile

Regulatory documentation confirms that the interaction structure is defined primarily by physicochemical incompatibility and specific administration constraints, reflecting the product's nature as an intravenous biological solution. The regulatory profile explicitly prohibits mixing with non-isotonic fluids and confirms the absence of documented metabolic or transporter-mediated drug interactions with small molecule drugs, food, or herbal products.

Mechanism of Action

Core Mechanism: Wnt/beta-Catenin Pathway Agonism

Alburex acts as a modulator of the Wnt/beta-catenin signaling cascade. Alburex is an agonist of the LRP5/ LRP6 coreceptors, initiating signal transduction across the cellular membrane. This receptor binding facilitates the stabilization of beta-catenin within the cytoplasm. This stabilization prevents beta-catenin degradation by the destruction complex and promotes its subsequent nuclear translocation.

Once in the nucleus, beta-catenin binds to TCF/ LEF transcription factors. This complex alters the transcription profile of target genes involved in the regulation of osteoblast differentiation and function. This modulation affects downstream cellular processes, including the expression of osteoprotegerin ( OPG) and the RANKL/ RANK ratio, thereby influencing osteoclastogenesis and bone turnover.

Dosage and Administration Information

Alburex is administered exclusively as a solution for intravenous infusion via a parenteral route, requiring the supervision of a healthcare professional in a dedicated clinical setting. The product is available in concentrations typically 5% and 20% (or 25%), and is never administered orally.

The fundamental principle governing its use is that the overall dosage and administration rate must be carefully tailored to the patient's individual clinical requirements, with volume and infusion speed adapted according to their hemodynamic stability. Dosing is typically specified in grams of human albumin. For example, the initial dose for acute hypovolemia is 25 g, which may be repeated if the patient does not achieve stability within 15 to 30 minutes. Certain regimens follow a set duration, such as once-daily administration for 7 to 10 days when used to support patients with acute nephrosis.

Proper preparation is mandatory and follows a strictly defined protocol. The solution may be diluted with 0.9% saline or 5% dextrose but must not be diluted with sterile water for injection due to known incompatibility issues. Furthermore, if large volumes are administered, the solution should be warmed to room or body temperature prior to the start of the infusion. In both the pediatric and older adult populations, the dosage and rate of infusion must be adapted according to individual needs.

Recent Clinical Evidence

Research evidence / Overview of studies for Alburex

Research Evidence for Restoring Circulating Blood Volume

This section will summarize the structure of the high-level research, including Randomized Controlled Trials (RCTs), that was studied for Human Albumin solutions in conditions involving acute blood volume deficiency (hypovolemia) and shock. The summary will focus on what studies measured, such as hemodynamic stability markers and patient survival.

Research has extensively explored the evaluation of albumin preparations in emergency and critical care settings to address temporary physiological imbalance caused by the rapid loss of blood volume. Randomized Controlled Trials and large meta-analyses have studied albumin by comparing it with other types of intravenous fluids. Researchers focused on outcomes monitoring physiological strain or stress, including maintaining stable blood pressure and tracking patient survival rates over short-term periods. Findings describe patterns observed in the studies regarding fluid volume maintenance. Data show patterns related to patient survival that were mixed. What remains uncertain is the consistent pattern of outcomes across all specific patient subgroups.

Clinical Evaluation for Low Plasma Protein Levels (Hypoalbuminemia)

This part will review the research that investigated the measured changes following administration to patients with significantly low protein levels in the blood. It will specifically outline the studies that tracked changes in serum albumin concentration and measured changes related to severe edema (swelling).

Albumin was evaluated in research exploring the effects of hypoproteinemia. Studies focused on monitoring changes in the amount of protein present in the blood. Research highlights changes measured during the study period, noting that administration was observed in some studies to achieve correction or maintenance of protein concentrations in the blood. Studies reported how changes in protein levels were associated with observed changes in systemic edema. However, the strongest and most consistent patterns findings indicate were seen in highly specific contexts, such as patients with severe burn injury.

Studies Focused on Fluid Balance in Liver and Kidney Conditions

This segment will detail the evidence base for specific evaluations in conditions that impact fluid distribution, particularly the body of RCTs related to liver cirrhosis (e.g., following large-volume fluid removal procedures) and the smaller studies addressing acute kidney conditions (nephrotic syndrome).

A significant body of Randomized Controlled Trials has focused on the use of albumin in patients with liver cirrhosis. These studies specifically tracked measured outcomes related to Post-Paracentesis Circulatory Dysfunction (PICD) and monitored patient survival. For other conditions, such as acute kidney conditions and severe Acute Respiratory Distress Syndrome (ARDS), the evidence is limited, relying mostly on smaller studies. Research suggests that when combined with diuretics, the preparation may assist in achieving fluid balance goals, but sample sizes were modest and the results apply only to the populations studied.

Areas of Scientific Uncertainty and Research Gaps

Comparative evidence is lacking in the sense that optimal use is not fully established for all indications. Research continues to clarify the measured outcomes in situations where albumin was studied for comparison against alternative fluid types. Long-term effects are not fully established, requiring further research observing responses over defined time intervals.

Key Studies & References NIH National Library of Medicine - Human Albumin Monograph (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Alburex (FAQ)

Q: What are the most common side effects of Alburex?

A: The official product information describes the most frequent adverse reactions as uncommon, meaning they are expected to affect between 1 and 10 out of every 1,000 users. These are generally mild, infusion-related symptoms that include nausea, vomiting, fever, chills, and flushing of the skin. These effects are typically managed by adjusting the rate of administration under professional supervision.

Q: Can I take Alburex with common over-the-counter pain relievers?

A: Regulatory information indicates an absence of documented metabolic or transporter-mediated drug interactions with small-molecule drugs like many over-the-counter (OTC) pain relievers. However, since Alburex is an intravenous solution, the product is specified as being not intended to be mixed with any other medicines during administration.

Q: What should I know about taking Alburex with food or drinks?

A: Regulatory documents state that Alburex is specified as not compatible with solutions containing alcohol to prevent the solution from destabilizing. Outside of this administration restriction, the official product information indicates there are no documented interactions with food or herbal products.

Q: What happens to the drug's effectiveness if I take it for a long period of time?

A: The duration of the fluid-balancing effect is highly dependent on the patient's individual clinical condition and needs. Research indicates that the albumin in the body has an average half-life of approximately 19 days. The official labeling does not establish whether sustained long-term use leads to a reduced effect.

Q: Does Alburex have any known effect on kidney function?

A: The regulatory label advises caution when administering Alburex to patients who are sensitive to fluid overload, such as those with certain states of renal anuria (lack of urine production). Despite this caution, official research has examined the use of the medicine in some acute kidney conditions, which is reflected in its therapeutic profile.

Q: What are the general safety statistics reported for Alburex?

A: Based on large-scale safety reports and pharmacovigilance data, both non-fatal and fatal serious adverse events for human albumin products are considered very rare. Incidences of severe reactions are typically tracked and reported using frequency classifications as defined by regulatory bodies.

Q: Does Alburex cause weight gain or weight loss?

A: Weight change is not listed as a specific adverse reaction in the official product information. However, the label contains a safety warning regarding the risk of volume overload (hypervolemia). The warning concerns a state of excessive fluid retention, which can be associated with temporary weight increase.

Q: How long does it typically take for Alburex to start working?

A: The effect of Human Albumin on the circulating blood volume is measurable rapidly. Official clinical data indicate that the intended volume-expanding effect can be observed within 15 minutes of starting the administration.

Q: Is it common to feel unusually tired while taking Alburex?

A: Feeling unusually tired or weak is sometimes listed in regulatory documents as an adverse reaction, though the official product information does not specify how common this symptom is.

Q: Can a person with pre-existing liver problems use Alburex?

A: Yes, Alburex is listed in official documents as being indicated for specific uses in patients with pre-existing liver problems. For instance, official documentation lists the management of certain complications of liver cirrhosis as part of its approved therapeutic indications.

Q: Is Alburex a brand-name drug, or is a generic available?

A: Alburex is the brand name for the active ingredient, Human Albumin. Because Human Albumin is a biological product derived from human plasma, it is classified differently from traditional small-molecule generic drugs, though multiple manufacturers produce other authorized versions of the active ingredient, Human Albumin.

Q: Does Alburex affect my ability to drive or operate machinery?

A: Official regulatory documents explicitly state that based on the product’s known effects, no indications have been observed that human albumin impairs a patient's ability to drive or use machinery. This is because the medicine is primarily a volume expander.

Q: Is Alburex a controlled substance in the US or other countries?

A: Alburex (Human Albumin) is classified by regulatory authorities as a biological product or plasma derivative. It is not listed as a controlled substance under the US Controlled Substances Act or similar international classifications.

Q: What is the duration of action for a single dose of Alburex?

A: The half-life of the albumin protein in the body is approximately 19 days in a healthy individual. While the volume expansion effect of a single dose can persist for many hours, the overall stability of the protein in the body is longer-lasting.

Q: Can I use Alburex if I have a known allergy to other medications?

A: The primary contraindication listed in the regulatory label is a known hypersensitivity (allergy) to human albumin itself or any other ingredient in the formulation. The label does not provide general cross-reactivity guidance for allergies to unrelated medications.

Q: How do doctors monitor the safety of patients taking Alburex long-term?

A: Regulatory documents require healthcare professionals to regularly monitor the patient’s hemodynamic performance (such as blood pressure and pulse rate) and electrolyte status during administration. These regulatory requirements describe the necessity of monitoring performance to guard against the risks of circulatory overload.

Q: Does Alburex affect my mental clarity?

A: Mental clarity is not directly addressed as an adverse effect. However, official safety documents mention headache as a possible adverse reaction, which could be a non-specific symptom of a reaction or a sign of potential volume changes in the body.

Q: Can taking Alburex affect my sleep patterns?

A: Sleep patterns are not directly listed as an adverse effect of Alburex. However, the official side effect list includes reactions such as fever, chills, and fast heart rate (tachycardia), which are symptoms that may indirectly affect sleep quality.

How should Alburex be stored and disposed of?

How to Store and Dispose of Alburex

Alburex (Albumin Human) must be stored under specific environmental and handling conditions defined in regulatory labeling to maintain its stability.

Storage Requirements

Condition	Requirement
Temperature Limit	Store at a temperature not exceeding 30°C (86°F).
Freezing Prohibition	The solution must not be frozen.
Protection	Store in the original container to protect the solution from light.
Child Safety	Keep out of the sight and reach of children.

Stability and Disposal

Since the product does not contain antimicrobial preservatives, the infusion must be started within four hours of puncturing the vial stopper. Any unused Alburex solution or waste material must be handled and discarded in accordance with local regulatory requirements, and should not be disposed of via household waste or wastewater.

Alburex